Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12

Journal of the National Cancer Institute

Volumn 89, Issue 14, 1997, Pages 1049-1058

  Cavallo, Federica ^a   Signorelli, Paola ^b   Giovarelli, Mirella ^a   Musiani, Piero ^b   Modesti, Andrea ^b   Brunda, Michael J ^c   Colombo, Mario P ^d   Forni, Guido ^a,e  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c HOFFMANN LA ROCHE INC   (United States)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e SAN LUIGI GONZAGA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7; RECOMBINANT INTERLEUKIN 12; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; CARCINOMA CELL; CONTROLLED STUDY; FEMALE; GENETIC ENGINEERING; IMMUNE DEFICIENCY; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN;

EID: 0030739621     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/89.14.1049     Document Type: Article

References (46)

1. Forni G, Foa R, Santoni A, Frati L, editors. Cytokine-induced tumor immunogenicity. From exogenous molecules to gene therapy. London: Academic Press, 1994.
2. Dranoff G, Mulligan RC. Gene transfer as cancer therapy. Adv Immunol 1995;58:417-54.
3. Forni G, Pericle F, Giovarelli M. Effects of local cytokine therapy. In: Gearing A, Rossio J, Oppenheim JJ, editors. Clinical applications of cytokines: role in pathogenesis, diagnosis and therapy. New York: Oxford University Press, 1993:187-94.
4. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting antitumor immunity. Proc Natl Acad Sci U S A 1993;90: 3539-43.
5. Cavallo F, Di Pierro F, Giovarelli M, Gulino A, Vacca A, Stoppacciaro A, et al. Protective and curative potential of vaccination with interleukin-2-gene-transfected cells from a spontaneous mouse mammary adenocarcinoma. Cancer Res 1993;53:5067-70.
6. Allione A, Consalvo M, Nanni P, Lollini PL, Cavallo F, Giovarelli M, et al. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor α, granulocyte-macrophage colony-stimulating factor, and γ-interferon gene or admixed with conventional adjuvants. Cancer Res 1994;54:6022-6.
7. Cavallo F, Giovarelli M, Gulino A, Vacca A, Stoppacciaro A, Modesti A, et al. Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene transfection. J Immunol 1992;149:3627-35.
8. Trinchieri G. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 1995;84:4008-27.
9. Trembleau S, Germann T, Gately MK, Adorini L. The role of IL-12 in the induction of organ-specific autoimmune diseases. Immunol Today 1995; 16:383-6.
10. Tahara H, Zeh HJ 3rd, Storkus WJ, Pappo I, Watkins SC, Gubler U, et al. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res 1994;54:182-9.
11. Zitvogel L, Tahara H, Robbins PD, Storkus WJ, Clarke MR, Nalesnik MA, et al. Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts. J Immunol 1995;155:1393-403.
12. Tahara H, Zitvogel L, Storkus WJ, Zeh HJ 3rd, McKinney TG, Schreiber RD, et al. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol 1995;154: 6466-74.
13. Meko JB, Yim HJ, Tsung K, Norton JA. High cytokine production and effective antitumor activity of a recombinant vaccinia virus encoding murine interleukin 12. Cancer Res 1995;55:4765-70.
14. Martinotti A, Stoppacciaro A, Vagliani M, Melani C, Spreafico F, Wysocka M, et al. CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes. Eur J Immunol 1995;25:137-46.
15. Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, et al. Antitumor and antimetastatic activity of Interleukin 12 against murine tumors. J Exp Med 1993;178:1223-30.
16. Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, Brunda MJ, et al. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J Immunol 1994;153:1697-706.
17. Mu J, Zou JP, Yamamoto N, Tsutsui T, Tai XG, Kobayashi M, et al. Administration of recombinant interleukin 12 prevents outgrowth of tumor cells metastasizing spontaneously to lung and lymph nodes. Cancer Res 1995;55:4404-8.
18. Noguchi Y, Jungbluth A, Richards EC, Old LJ. Effect of interleukin 12 on tumor induction by 3-methylcholanthrene. Proc Natl Acad Sci U S A 1996; 93:11798-801.
19. Vagliani M, Rodolfo M, Cavallo F, Parenza M, Melani C, Parmiani G, et al. Interleukin 12 potentiates the curative effect of a vaccine based on interleukin 2-transduced tumor cells. Cancer Res 1996;56:467-70.
20. Tannenbaum CS, Wicker N, Armstrong D, Tubbs R, Finke J, Bukowski R, et al. Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12. J Immunol 1996;156:693-9.
21. Colombo MP, Forni G. Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol Today 1994;15:48-51.
22. Musiani P, Allione A, Modica A, Lollini PL, Giovarelli M, Cavallo F, et al. Role of neutrophils and lymphocytes in inhibition of a mouse mammary adenocarcinoma engineered to release IL-2, IL-4, IL-7, IL-10, IFN-alpha, IFN-gamma, and TNF-alpha. Lab Invest 1996;74:146-57.
23. Ferrantini M, Giovarelli M, Modesti A, Musiani P, Modica A, Venditti M, et al. IFN-alpha 1 gene expression into a metastatic murine adenocarcinoma (TS/A) results in CD8+ T cell-mediated tumor rejection and development of antitumor immunity. Comparative studies with IFN-gamma-producing TS/A cells. J Immunol 1994;153:4604-15.
24. Nanni P, de Giovanni C, Lollini PL, Nicoletti G, Prodi G. TS/A: a new metastasizing cell line from a BALB/c spontaneous mammary adenocarcinoma. Clin Exp Metastasis 1983;1:373-80.
25. Giovarelli M, Musiani P, Modesti A, Dellabona P, Casorati G, Allione A, et al. Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory. J Immunol 1995;155:3112-23.
26. Nicoletti G, de Giovanni C, Lollini PL, Bagnara GP, Scotlandi K, Landuzzi L, et al. In vivo and in vitro production of haemotopoietic colony-stimulating activity by murine cell lines of different origin: a frequent finding. Eur J Cancer Clin Oncol 1989;25:1281-6.
27. Pericle F, Giovarelli M, Colombo MP, Ferrari G, Musiani P, Modesti A, et al. An efficient Th-2-type memory follows CD8+ lymphocyte-driven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4. J Immunol 1994;153:5659-73.
28. Lollini P, Bosco MC, Cavallo F, De Giovanni C, Giovarelli M, Landuzzi L, et al. Inhibition of tumor growth and enhancement of metastasis after transfection of the γ-interferon gene. Int J Cancer 1993;55:320-9.
29. Colombo MP, Vagliani M, Spreafico F, Parenza M, Chiodoni C, Melani C, et al. Amount of interleukin 12 available at the tumor site is critical for tumor regression. Cancer Res 1996;56:2531-4.
30. Vecchi A, Garlanda C, Lampugnani MG, Resnati M, Matteucci C, Stoppacciaro A, et al. Monoclonal antibodies specific for endothelial cells of mouse blood vessels. Their application in the identification of adult and embryonic endothelium. Eur J Cell Biol 1994;63:247-54.
31. Hock H, Dorsch M, Kunzendorf U, Uberla K, Qin Z, Diamantstein T, et al. Vaccinations with tumor cells genetically engineered to produce different cytokines: effectivity not superior to a classical adjuvant. Cancer Res 1993; 53:714-6.
32. Colombo MP, Modesti A, Parmiani G, Forni G. Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. Cancer Res 1992;52:4853-7.
33. Consalvo M, Mullen CA, Modesti A, Musiani P, Allione A, Cavallo F, et al. 5-Fluorocytosine-induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory. J Immunol 1995; 154: 5302-12.
34. Roth JA, Cristiano RJ. Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst 1997;89:21-39.
35. Wigginton JM, Kuhns DB, Back TC, Brunda MJ, Wiltrout RH, Cox GW. Interleukin 12 primes macrophages for nitric oxide production in vivo and restores depressed nitric oxide production by macrophages from tumor-bearing mice: implications for the antitumor activity of interleukin 12 and/ or interleukin 2. Cancer Res 1996;56:1131-6.
36. Luster AD, Leder P. IP-10, a -C-X-C-chemokine, elicits a potent thymus-dependent antitumor response in vivo. J Exp Med 1993;178:1057-65.
37. Sgadari C, Angiolillo AL, Tosato G. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 1996; 87:3877-82.
38. Fujiwara H, Clark SC, Hamaoka T. Cellular and molecular mechanisms underlying IL-12-induced tumor regression. Ann N Y Acad Sci 1996;795: 294-309.
39. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 1995;87:581-6.
40. Nathan C, Sporn M. Cytokines in context. J Cell Biol 1991;113:981-6.
41. Wang ZE, Zheng S, Corry DB, Dalton DK, Seder RA, Reiner SL, et al. Interferon γ-independent effects of interleukin 12 administered during acute or established infection due to Leishmania major. Proc Natl Acad Sci USA 1994;91:12932-6.
42. Stoppacciaro A, Melani C, Parenza M, Mastracchio A, Bassi C, Baroni C, et al. Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T cell-produced interferon gamma. J Exp Med 1993;178:151-61.
43. Westlin WF, Gimbrone MA Jr. Neutrophil-mediated damage to human vascular endothelium. Role of cytokine activation. Am J Pathol 1993;142: 117-28.
44. Cavallo F, Martin-Fontecha A, Bellone M, Heltai S, Gatti E, Tornaghi P, et al. Coexpression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response. Eur J Immunol 1995;25:1154-62.
45. Martin-Fomecha A, Cavallo F, Bellone M, Heltai S, Iezzi G, Tornaghi P, et al. Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors. Eur J Immunol 1996;26:1851-9.
46. Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT, et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells. B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996;183:87-97.